Photodynamic therapy gains FDA approval for superficial BCC - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

  • By

  • Kathryn Wighton

  • September 15, 2026

  • 2 min

Share

Original Source(s)

Photodynamic therapy gains FDA approval for superficial BCC

  • by Kathryn Wighton

  • September 15, 2026

Related Content

Use of digital health interventions by outdoor workplaces in Australia: A focus on skin cancer prevention interventions

Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice